Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Income towards Parent Company: 2023-2024

Historic Income towards Parent Company for CG Oncology (CGON) over the last 2 years, with Dec 2024 value amounting to -$88.0 million.

  • CG Oncology's Income towards Parent Company fell 114.22% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.4 million, marking a year-over-year decrease of 107.99%. This contributed to the annual value of -$88.0 million for FY2024, which is 81.36% down from last year.
  • Per CG Oncology's latest filing, its Income towards Parent Company stood at -$88.0 million for FY2024, which was down 81.36% from -$48.5 million recorded in FY2023.
  • CG Oncology's 5-year Income towards Parent Company high stood at -$48.5 million for FY2023, and its period low was -$88.0 million during FY2024.
  • Moreover, its 2-year median value for Income towards Parent Company was -$68.3 million (2023), whereas its average is -$68.3 million.
  • Data for CG Oncology's Income towards Parent Company shows a maximum YoY plummeted of 81.36% (in 2024) over the last 5 years.
  • Over the past 2 years, CG Oncology's Income towards Parent Company (Yearly) stood at -$48.5 million in 2023, then plummeted by 81.36% to -$88.0 million in 2024.